Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitors.

1 Herding is particularly prevalent in oncology drug development where it is an increasing trend. 1 Herding was described in the financial marketplace as ‘an intrinsic preference for conformity’ that is ‘influenced by others’ actions’ with ‘herds that charge into risky ventures without adequate information and appreciation of the risk-rewards trade-offs’. 2 Herding is especially prevalent in the field of cancer immunotherapy.

also in 63,971 other papers